Revenue is up $2.2 million (or 13.3%) to $19.2 million with strong growth in Export sales, which were $872k, up $405k (or 86%).
We now export to the USA, Europe, the Middle East and New Zealand.
Gross margin is a pleasing 34% and slightly ahead of the 2017 result.
EBITDA of $1.4 million is up 71% on the previous year.
Profit after tax of $710k representing a $591k improvement on last year. There is minimal tax expense this year as the company continues to have tax losses that have not been recognized as an asset. There is no tax payable for 2018.
We have generated $1.47 million in operating cash flows from strong working capital management and profits generated.
Our new crash-tested products have been submitted for the necessary regulatory approvals in the USA and Australia.
Strong order book with $4.6 million work in hand (up 64% from the same period last
year)
Net debt to equity down a further 5% to 15.6%
- Forums
- ASX - By Stock
- Ann: Appendix 4E and Annual Financial Report
SRH
saferoads holdings limited
Add to My Watchlist
0.00%
!
8.5¢

Revenue is up $2.2 million (or 13.3%) to $19.2 million with...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
8.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.714M |
Open | High | Low | Value | Volume |
8.5¢ | 8.5¢ | 8.5¢ | $595 | 6.999K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50001 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.5¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50001 | 0.084 |
1 | 10000 | 0.080 |
2 | 170000 | 0.072 |
2 | 40000 | 0.050 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.095 | 30000 | 1 |
0.100 | 52254 | 1 |
0.150 | 12600 | 1 |
0.175 | 63254 | 2 |
0.000 | 0 | 0 |
Last trade - 12.11pm 04/07/2025 (20 minute delay) ? |
Featured News
SRH (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online